Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I hydroxyurea plus dose-intense temozolomide in recurrent glioblastoma
NL-OMON50467Phase 1Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxyurea and temozolomide in glioblastoma (GBM), sponsored by Vrije University Medical Center. Primary endpoints: Maximum tolerated dose of hydroxyurea in combination with temozolomide and Safety profile. Started Mar 2018; status: active, not recruiting.
02
Drugs
hydroxyureatemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON50467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50467.